Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.
P/B ratio for Advaxis, Inc. (ADXS)
P/B ratio as of 2023: -0.16
According to Advaxis, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is -0.16. At the end of 2022 the company had a P/B ratio of 0.14.
P/B ratio history for Advaxis, Inc. from 2002 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | -0.16 |
| 2022 | 0.14 |
| 2021 | 1.68 |
| 2020 | 0.68 |
| 2019 | 0.33 |
| 2018 | 97.11 |
| 2017 | 205.21 |
| 2016 | 193.98 |
| 2015 | 217.27 |
| 2014 | 213.07 |
| 2013 | 84.13 |
| 2012 | -195.49 |
| 2011 | -206.82 |
| 2010 | -127.68 |
| 2009 | -77.12 |
| 2008 | -215.47 |
| 2007 | 190.03 |
| 2006 | -164.27 |
| 2005 | 420.96 |
| 2004 | -3037.77 |
| 2003 | 0.00 |
| 2002 | 0.00 |